Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity
Open Access
- 14 November 2017
- journal article
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 15 (8) , 1192-1207
Abstract
Background: The treatment of schizophrenia is challenging due to the wide range of symptoms (positive, negative, cognitive) associated with the disease. Typical antipsychotics that antagonize D2 receptors are effective in treating positive symptoms, but extrapyramidal side-effects (EPS) are a common occurrence. Atypical antipsychotics targeting 5-HT2A and D2 receptors are more effective at treating cognitive and negative symptoms compared to typical antipsychotics, but these drugs also result in side-effects such as metabolic syndromes. Objective: To identify evidence in the literature that elucidates the pharmacological profile of aripiprazole.s. Methods: We searched PubMed for peer reviewed articles on aripiprazole and its clinical efficacy, side-effects, pharmacology, and effects in animal models of schizophrenia symptoms. Results: Aripiprazole is a newer atypical antipsychotic that displays a unique pharmacological profile, including partial D2 agonism and functionally selective properties. Aripiprazole is effective at treating the positive symptoms of schizophrenia and has the potential to treat negative and cognitive symptoms at least as well as other atypical antipsychotics. The drug has a favorable side-effect profile and has a low propensity to result in EPS or metabolic syndromes. Animal models of schizophrenia have been used to determine the efficacy of aripiprazole in symptom management. In these instances, aripiprazole resulted in the reversal of deficits in extinction, pre-pulse inhibition, and social withdrawal. Because aripiprazole requires a greater than 90% occupancy rate at D2 receptors to be clinically active and does not produce EPS, this suggests a functionally selective effect on intracellular signaling pathways. Conclusion: A combination of factors such as dopamine system stabilization via partial agonism, functional selectivity at D2 receptors, and serotonin-dopamine system interaction may contribute to the ability of aripiprazole to successfully manage schizophrenia symptoms. This review examines these mechanisms of action to further clarify the pharmacological actions of aripiprazole.Keywords
This publication has 102 references indexed in Scilit:
- The Akt–GSK-3 signaling cascade in the actions of dopamineTrends in Pharmacological Sciences, 2007
- Schizophrenia as a GSK-3 dysregulation disorderTrends in Neurosciences, 2007
- Pharmacokinetics, Tolerability, and Safety of Aripiprazole following Multiple Oral Dosing in Normal Healthy VolunteersThe Journal of Clinical Pharmacology, 2004
- AripiprazoleDrugs, 2004
- Glutamate, Dopamine, and SchizophreniaAnnals of the New York Academy of Sciences, 2003
- Prenatal cocaine exposure alters glycogen synthase kinase-3β (GSK3β) pathway in select rabbit brain areasNeuroscience Letters, 2003
- The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A pet studyLife Sciences, 1995
- Supersensitivity of striatal D2 dopamine receptors mediating inhibition of adenylate cyclase and stimulation of guanosine triphosphatase following chronic administration of haloperidol in miceNeuroscience Letters, 1987
- Dopamine receptors and the dopamine hypothesis of schizophreniaSynapse, 1987
- Selective decrease in the affinity of D2 dopamine receptor for agonist induced by islet-activating protein, pertussis toxin, associated with ADP-ribosylation of the specific membrane protein of bovine striatumBiochemical and Biophysical Research Communications, 1983